Investments	9 Months Ended
Sep. 30, 2015
Notes to Financial Statements
Note 4. Investments	In May 2011, FluoroPharma, Inc. (“FPI”) entered into a reverse merger with FluoroPharma Medical, Inc. (“FPMI”). In connection with this transaction, the Company's warrants to purchase FPI common stock were exchanged for warrants in FPMI (the “FPMI Warrants”). During 2012, the Company recognized a gain in the amount of $115,752 as a result of the issuance of certain of these warrants to holders of promissory notes of the Company that matured during the period. During the period ended September 30, 2014, the Company assigned its remaining 109,917 FPMI Warrants, with an exercise price of $1.00 and expiring on February 15, 2019 to Burnham Hill Advisors, LLC (“BHA”) in exchange for the extension of BHA’s previous cash deferral agreement through December 31, 2014. Following the transaction, the Company recognized a gain on the exchange in the amount of $20,660 and no longer held FPMI warrants. In May 2006, the Company purchased 144,024 shares of common stock of Genomics USA, Inc. (“GUSA”) for $200,000. After the investment, QuantRx owned approximately 5% of the total issued and outstanding common stock of GUSA. As of the end of September 30, 2015, the Company’s position had been diluted to less than 5% of the issued and outstanding common stock of GUSA, and it is expected that the Company’s position will continue to be diluted in the future. The investment is recorded at historical cost and is assessed at least annually for impairment. GUSA now does business as GMS Biotech. Pursuant to the Global LOI described in Note 1 above, under the heading “Recent Developments”, in September 2015, the Company advanced to Global Cancer Diagnostics, Inc. $50,000 during the quarter ended September 30, 2015, which amount is due and payable by Global, on demand, anytime after the Termination Date of the Global LOI. In the event the Company and Global execute definitive merger documents contemplated by the Global LOI on or before the Termination Date, Global will issue to the Company that number of shares of Global’s common stock equal to 10% of the then outstanding shares of Global’s common stock, on a fully-diluted basis as payment of the Global Advance.

- Definition

Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.

+ References + Details